NASDAQ · CHRS
Healthcare · Biotechnology
$0.83
Down-$0.08 (-9.72%)
Updated Nov 2, 2026, 10:58 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CHRS
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
CHRS closed at $0.83 after 20 trading sessions, down 25.88% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $0.90 | $0.9177 | $0.8239 | $0.8301 | 2.19M |
| Oct 29, 2026 | $1.15 | $1.15 | $0.805 | $0.8984 | 6.14M |
| Oct 28, 2026 | $1.08 | $1.17 | $1.05 | $1.16 | 1.41M |
| Oct 27, 2026 | $1.03 | $1.07 | $1.01 | $1.07 | 605.84K |
| Oct 26, 2026 | $1.01 | $1.02 | $0.98 | $1.01 | 686.79K |
| Oct 23, 2026 | $1.03 | $1.038 | $0.9881 | $1.01 | 641.45K |
| Oct 22, 2026 | $1.02 | $1.06 | $1.015 | $1.05 | 641.95K |
| Oct 21, 2026 | $1.01 | $1.05 | $1.005 | $1.02 | 1.28M |
| Oct 20, 2026 | $0.96 | $1.03 | $0.955 | $1.00 | 967.7K |
| Oct 19, 2026 | $1.00 | $1.015 | $0.94 | $0.9587 | 1.73M |
| Oct 16, 2026 | $1.07 | $1.07 | $0.9868 | $0.99 | 938.5K |
| Oct 15, 2026 | $1.07 | $1.09 | $1.03 | $1.07 | 1.54M |
| Oct 14, 2026 | $1.05 | $1.085 | $1.011 | $1.05 | 1.72M |
| Oct 13, 2026 | $1.06 | $1.08 | $1.00 | $1.07 | 1.34M |
| Oct 12, 2026 | $1.06 | $1.066 | $1.03 | $1.03 | 1.04M |
| Oct 9, 2026 | $1.06 | $1.12 | $1.05 | $1.07 | 1.7M |
| Oct 8, 2026 | $1.01 | $1.07 | $0.974 | $1.07 | 2.14M |
| Oct 7, 2026 | $1.02 | $1.08 | $1.01 | $1.01 | 1.23M |
| Oct 6, 2026 | $1.13 | $1.13 | $1.01 | $1.03 | 2.97M |
| Oct 5, 2026 | $1.16 | $1.16 | $1.08 | $1.12 | 2.01M |
The latest Smart Investors Daily articles mentioning CHRS.
Company
Market Activity
Research & News
CHRS research
Company profile and research snapshot.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Buy | — |
| May 11, 2026 | Guggenheim | Buy | — |
| Jan 22, 2026 | Oppenheimer | Outperform | — |
| Sep 4, 2025 | Maxim Group | Buy | — |
| Apr 29, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 29, 2026
HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Coherus Oncology (NASDAQ:CHRS) with a Buy rating and announces Price Target of $7.
SeekingAlpha · Oct 29, 2026
Coherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer October 28, 2026 4:30 PM EDTCompany ParticipantsCarrie Graham...
Yahoo · Oct 29, 2026
Coherus Oncology (NASDAQ:CHRS) presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several solid-tumor settings. The company highlighted early activity in esophageal squamous cell carcinoma, or ESCC, and said it plans to
Yahoo · Oct 28, 2026
-1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients- -2L ESCC durable clinical benefit observed with a clear dose-response irrespective of PD-L1 status and in PD-1 refractory patients- - Anti-tumor activity demonstrated across five indications and over 120 patients, including HPV-positive head and neck and GI tumors- - Acceptable and manageable safety profile, with no new safety signals to date supports continued developmen
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CHRS.
